InvestorsHub Logo
Followers 50
Posts 6343
Boards Moderated 0
Alias Born 01/22/2006

Re: None

Wednesday, 12/20/2017 7:56:14 PM

Wednesday, December 20, 2017 7:56:14 PM

Post# of 733
Here is a link to the NICE report (note there are some detailed PDF's available from this page)
https://www.nice.org.uk/guidance/indevelopment/gid-hst10009/consultation/html-content

Don't know why anyone is surprised if NICE didn't initially recommend Vertex's CF drugs there was no way they would recommend Scenesse especially if the company is sticking to the "uniform pricing" nonsense. Since they apparently have limited bandwidth to pursue concurrent reimbursements this should have been (very) low on the priority unless they were open to price negotiations (the main objective of NICE). Just another dumb decision by management no surprise here.